Healthcare

Against the prior corresponding period, revenue was up $1.7 million, or 4.8%, EBITDA was up $1.01 million, or 197.5%, and operational expenditure was down $685,000, or 9.5%. The release does not state absolute EBITDA or revenue figures, though it describes the company's focus as …

Revenue rose 6.1% to A$48.305 million from A$45.544 million. Profit before income tax rose 19.1% to A$8.078 million and net profit after tax rose 14.9% to A$5.541 million, with A$5.559 million attributable to members. Net tangibleAssetsper security were A$0.92 against A$0.89. The company says …

In line with expectations set out in the 7 July quarterly report, Zoono received further shelf-life extension orders of circa NZ$700,000 in July. The company reports unaudited July sales of NZ$625,000 and an unaudited profit of NZ$110,000 for the month. The release does not …

Mr Phizacklea is Senior Vice President, Global StrategicMarketingat Cochlear and has more than 30 years' experience in the global medical technology sector, spanning commercial leadership, market access, clinical affairs and growth strategy. He previously held senior executive roles at Cochlear and Abbott.

On 2 September 2026 the company announced that the Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma (CTCL) had reached its pre-specified enrolment threshold for the first planned Dose Optimisation Committee (DOC) review. Ten evaluable patients have been enrolled in …

The OLE enables patients who complete Part C of the Phase 1b trial to receive PYC-003 continuously for up to 24 months, mirroring the duration of the registrational trial planned after the Phase 1b study. The first enrolled patient has finished dosing in the …

The SRC reviewed all safety data from both Cohort 1 patients, who received RC220 at 50 mg/m2 with osimertinib at 80 mg daily. No dose-limiting toxicities or treatment-related safety concerns were identified in either patient during the safety observation period. The second patient had …